Response to lapatinib appears to be affected by HER protein expression in patients with inflammatory breast cancer

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1629, 2008-01, pp. : 15-15

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Lapatinib no help in HER-2-negative breast cancer

By  

Inpharma, Vol. 1, Iss. 1663, 2008-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Effects of Esomeprazole on the Pharmacokinetics of Lapatinib in Breast Cancer Patients

By  

Clinical Pharmacology In Drug Development, Vol. 2, Iss. 4, 2013-10 ,pp. : 336-341

John Wiley & Sons Inc

Access to resources Recommend Favorite

Lapatinib Distribution in HER2 Overexpressing Experimental Brain Metastases of Breast Cancer

By Taskar Kunal   Rudraraju Vinay   Mittapalli Rajendar   Samala Ramakrishna   Thorsheim Helen   Lockman Julie   Gril Brunilde   Hua Emily   Palmieri Diane   Polli Joseph   Castellino Stephen   Rubin Stephen   Lockman Paul   Steeg Patricia   Smith Quentin  

Pharmaceutical Research, Vol. 29, Iss. 3, 2012-03 ,pp. : 770-781

Springer Publishing Company

Access to resources Recommend Favorite

Lapatinib: In Postmenopausal Women with Hormone Receptor-Positive, HER2-Positive Metastatic Breast Cancer

By Curran Monique P.  

Drugs, Vol. 70, Iss. 11, 2010-07 ,pp. : 1411-1422

Adis International

Access to resources Recommend Favorite

Lapatinib: A Review of its Use in the Treatment of HER2-Overexpressing, Trastuzumab-Refractory, Advanced or Metastatic Breast Cancer

By Frampton James E.  

Drugs, Vol. 69, Iss. 15, 2009-10 ,pp. : 2125-2148

Adis International

Access to resources Recommend Favorite